Axxam acquires a 240 000 carefully selected compounds library from Enamine for drug discovery programs

Axxam S.p.A., a contract research and discovery company, announced today that an entirely new generation screening collection is now available for drug discovery programs: AXX^DIV2.0 made up with 240 000 carefully selected small molecules.
Read press release